Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that 5α-reductase inhibitors (such as finasteride and dutasteride) effectively reduce prostate size and stabilize hair loss but are associated with sexual dysfunction; they remain essential treatments for BPH and androgenic alopecia, requiring tailored risk-benefit assessments.

This review analyzed clinical trials and guidelines on 5-α-reductase inhibitors (5-ARIs) and found these drugs significantly improve urinary symptoms in BPH and stabilize hair loss in androgenic alopecia, but may cause sexual dysfunction and gynecomastia.

In this review, 5α-reductase inhibitors like finasteride and dutasteride were found to significantly reduce prostate volume and stabilize hair loss, but they also carry risks of sexual dysfunction, necessitating careful patient evaluation and monitoring.

Finasteride can cause side effects like liver issues and hormonal changes.

This study presents a novel assay that allows for the simultaneous measurement of various androgens and 5α-reductase inhibitors in male serum, facilitating research into the biochemical effects of these inhibitors.

In this study, 17β-estradiol increased VEGF production in differentiated THP-1 cells, while dihydrotestosterone counteracted this effect by modulating adenylate cyclase activity.

This study found that exosomes derived from dental pulp mesenchymal stem cells (DPSC-Exos) significantly promoted hair regrowth and follicle density in a mouse model of androgenetic alopecia, showing similar efficacy to minoxidil by activating pathways that improve follicular vascularization and dermal papilla cell function.

In this study, the safety of finasteride in rats varied depending on dosing time, while its effectiveness on prostate weight reduction remained consistent.

This study found that increased expression of type II 5α-reductase, androgen receptors, and Hic-5/ARA55 in dermal papilla cells upregulates androgen sensitivity, playing a key role in androgenetic alopecia pathogenesis.

This review discusses recent advancements in understanding the use of 5 alpha-reductase inhibitors for benign prostatic hyperplasia, indicating that dual isoenzyme inhibitors like dutasteride may enhance treatment outcomes, but no new clinical results are presented.

This study found that dutasteride effectively improves symptoms of benign prostatic hyperplasia, showing benefits in urinary flow and quality of life, with only modestly elevated sexual side effects compared to placebo.

This review discusses the hormonal influences on prostate carcinogenesis and notes ongoing trials investigating whether finasteride could reduce prostate cancer incidence by inhibiting dihydrotestosterone synthesis, but it reports no new results.

This review discusses the comparative efficacy of dutasteride and finasteride for benign prostatic hyperplasia, reporting that while symptom improvements are similar, dutasteride may reduce prostate surgery risk and acute urinary retention more effectively.

This review highlights the potential therapeutic applications of nandrolone, an anabolic steroid, for male health, but notes that more human studies are needed due to limited existing literature.

This review discusses the safety of finasteride for male androgenic alopecia and benign prostatic hyperplasia, concluding it remains a viable option due to synergistic effects with other treatments and predictive measures for side effect risk.

This study reviewed recent scientific evidence on the neuroendocrine and metabolic impacts of chronic use of 5-alpha reductase inhibitors, detailing its association with sexual dysfunction, mood disorders, insulin resistance, and other metabolic disorders, suggesting persistent biopsycho-social risks beyond transient side effects in users.

This study found that 5-aminolevulinic acid combined with ferric ammonium citrate stimulated hair follicle growth and induced hair-like structures in human hair follicle models, suggesting its potential as a treatment for hair loss.

This study found that botulinum toxin type A inhibited apoptosis in dermal papillary cells induced by dihydrotestosterone through the circ_0135062/miR-506-3p/Bax axis.

This review examines the effects of sex hormones on hair growth and the pathogenesis of related hair disorders, highlighting current management benefits and controversies but reporting no new results.

This article presents a planned trial comparing radiotherapy and imiquimod for lentigo maligna treatment, noting a lack of direct evidence supporting current therapies, and aims to inform future treatment guidelines.

Different substances affect hair and skin cell growth in various ways.

Different substances affect hair and skin cell growth in various ways, with some promoting and others inhibiting cell proliferation.

Mouse hair cells respond to male hormones by growing less, and this can be stopped by certain blockers.

This study reports that perioperative use of dutasteride, both orally and through mesotherapy, may enhance hair graft survival and reduce shock loss in patients undergoing hair transplantation for androgenetic alopecia.

This study established a method to create stem cell-derived dermal papilla cells and found that their conditioned medium significantly boosts hair growth and offers anti-inflammatory benefits in mice, surpassing minoxidil and addressing androgen-related hair loss.

In this study, DHT inhibited hair regrowth and promoted hair follicle miniaturization in mice, with skin-resident myeloid cells enhancing their interaction with hair follicular cells, especially in females.

This study found that an octapeptide binding to Lgr5 can enhance the proliferation and differentiation of human primary hair cells by activating the Wnt/β-catenin signaling pathway, suggesting its potential as a treatment for hair loss in androgenetic alopecia.

This article discusses drugs with anti-androgenic effects and their mechanisms but reports no new research findings.

In this study, researchers found that crude extracts from Avicennia marina and its component avicequinone C inhibit mechanisms contributing to androgenic alopecia in vitro, including 5α-reductase activity and DHT-AR interactions, potentially promoting hair growth and delaying the catagen phase in human dermal papilla cells.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.